Aptamer’s  ongoing strategic asset development partnership with fast moving consumer goods (‘FMCG’) giant, Unilever plc (LSE: ULVR), has taken yet another important step forward, with a new paid work package that supports further development of deodorant Optimers. This latest extension for expanded stability testing is a critical advancement toward on-person trials and validates the superior performance the Group’s formulations have achieved to date. Partnering with Unilever, one of the world’s largest and most global FMCG companies, not only accelerates the technology's path to market but also opens doors to broader applications in personal care and beyond. Given that Unilever commanded >30% of 2024’s global US$27 billon deodorant market, this drives potential for Aptamer to collect significant long-term licencing revenues from topical, cosmetic applications that could potentially commercialise within the coming two or so years. With its recent £2m fundraising due to complete later this week plus an expanding fee-for service (‘FFS’) pipeline, the Group is expected have a cash runway sufficient to carry it through to 2027, by which time both this and various of its other strategically-partnered/inhouse developments can be expected to have reached critical value inflection points.